Cite
APA Citation
Fan, Y., Li, M., Ma, K., Hu, Y., Jing, J., Shi, Y., Li, E., & Dong, D. (2019). dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway. Cancer biology & therapy, 20(5), 617–632. http://access.bl.uk/ark:/81055/vdc_100081082350.0x000023